 recombin erythropoietin medicar payment biolog recombin human erythropoietin recent case studi great influenc feder polici medicar payment exert use cost medic technolog dialysi patient medicar predomin payer recombin erythropoietin anemia chronic renal diseas medicar leverag low US price product fix rate treatment biolog agent dialysi facil financi incent low dose medicar monitor patient respons august averag modal dose low patient month target hematocrit medicar financi incent payment polici qualiti care beneficiari